Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
*WATCH* Elevator Pitch with Oncimmune #ONC CEO, Dr Adam M Hill @OncimmuneECDT
https://www.voxmarkets.co.uk/articles/elevator-pitch-with-oncimmune-ceo-dr-adam-m-hill-651c0f3/
"@macmillancancer estimates up to 50,000 people could be living with undiagnosed #cancer because of delays to NHS services. In England alone, between March and August 2020, around 30,000 fewer people had started their first cancer treatment compared to the year before."
"Oncimmune Inks Contracts to Supply Blood-Based Lung Cancer Test to UK's NHS" @360DxNews
https://www.360dx.com/cancer/oncimmune-inks-contracts-supply-blood-based-lung-cancer-test-uks-nhs#.X9zh_On7TmH
EarlyCDT Lung selected for NICE Diagnostics Assessment Guidance that evaluates new diagnostic technologies in order to help NHS staff make efficient, cost-effective decisions about adopting new products in support of innovation, transformation & improving healthcare delivery.
"We urgently need to find ways to detect #lungcancer early, to drive up people's chances of a cure. This unique collaborative effort between universities, the NHS and companies with ground-breaking technologies is aimed at doing just that.” @PWMJohnson
https://www.southampton.ac.uk/news/2020/12/idx-lung-cancer-detection.page
Oncimmune taking part in "£10 million research collaboration to detect #lungcancer earlier"
https://www.southampton.ac.uk/news/2020/12/idx-lung-cancer-detection.page
#DetectCancerEarly @unisouthampton @UniversityLeeds @Roche @JNJNews @Inivata @BCPlatforms @PWMJohnson
Alongside industry colleagues, Oncimmune is proud to support Enhancing Cancer Care Through HealthTech – a new report highlighting how HealthTech can tackle the #COVID backlog and support the cancer targets set out in the #NHSLongTermPlan #LungCancer
https://www.abhi.org.uk/resource-hub/file/12437
Great to see the Early CDT Lung blood test gaining traction in NHS and lined up for NICE assessment. @Check4Cancer has pioneered this test in UK for private patients >50 with strong smoking history +/- family history of lung cancer. https://tinyurl.com/y23rkt7x @OncimmuneECDT #ONC
Gallery
